TVGN - Tevogen Bio Holdings Inc

TVGN - Tevogen Bio Holdings Inc

https://tevogen.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

GlobeNewswire • 5 days, 1 hour ago

WARREN, N.J., Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Tevogen ( "Tevogen Bio Holdings Inc." or "Company" ) ( Nasdaq: TVGN ) , today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + ...

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

GlobeNewswire • 5 days, 22 hours ago • score: 0.20

WARREN, N.J., Sept. 09, 2025 ( GLOBE NEWSWIRE ) -- Tevogen ( "Tevogen Bio Holdings Inc." or "Company" ) ( Nasdaq: TVGN ) , today shared asset value and potential forecast for the Company's pipeline product, TVGN 116, for liver cancer prevention with high-risk chronic Hepatitis B infections.

Tevogen Values TVGN-489 at $9-$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

GlobeNewswire • 1 week ago • score: 0.05

WARREN, N.J., Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- Tevogen ( "Tevogen Bio Holdings Inc." or "Company" ) ( Nasdaq: TVGN ) , today shared the risk-adjusted net present value ( rNPV ) estimate of $9 billion to $11 billion for TVGN-489, an allogeneic precision T cell therapy and the first ...

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

GlobeNewswire • 1 week, 3 days ago • score: 0.38

WARREN, N.J., Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Tevogen ( "Tevogen Bio Holdings Inc." or "Company" ) ( Nasdaq: TVGN ) , today shared asset value and potential forecast for the Company's pipeline product, TVGN 930, for treatment of non-solid tumor malignancies stemming from Epstein-Barr Virus ...

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

GlobeNewswire • 1 week, 4 days ago • score: 0.06

WARREN, N.J., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Tevogen ( "Tevogen Bio Holdings Inc." or "Company" ) ( Nasdaq: TVGN ) , today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune systems, who are at the highest risk of complications from the virus.

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

GlobeNewswire • 3 weeks, 2 days ago • score: 0.25

WARREN, N.J., Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Tevogen Bio Holdings Inc. ( "Tevogen" or the "Company" ) ( Nasdaq: TVGN ) , announced today that it has been named in BINJE's BEST Health Care 2025: Companies, Organizations and Service Providers.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-09 (Snapshot)

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. The company is headquartered in Warren, New Jersey.

52W High

$3.09

52W Low

$0.26

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.76

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

20.17

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

N/A

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

79.36%

Institutions (25–75% balanced)

2.57%

Shares Outstanding

196,705,000

Float

22,566,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-0.19

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

N/A

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0504

Previous

-0.0497

Trend

Falling

Signal Cross

No cross

As of

Sep. 05, 2025